Is PMOS the 'Diabetes of the Ovaries'? Expert Warns of India's Fertility Crisis
Anirudh Jain - Kolkata Bureau Jun 20, 2026 2,650 Views
MUMBAI — India is currently grappling with a severe demographic and reproductive healthcare challenge characterized by falling birth rates, rising subfertility, and a widespread hormonal disorder that medical professionals warn is frequently misdiagnosed. In a comprehensive medical briefing on Satur...
MUMBAI — India is currently grappling with a severe demographic and reproductive healthcare challenge characterized by falling birth rates, rising subfertility, and a widespread hormonal disorder that medical professionals warn is frequently misdiagnosed. In a comprehensive medical briefing on Saturday, June 20, 2026, Dr. Rishma Pai, one of the nation's premier gynecologists and a former president of the Federation of Obstetricians and Gynaecologists of India (FOGI), issued an urgent warning regarding the long-term systemic impact of Polycystic Ovary Syndrome. Dr. Pai emphasized that the condition—recently renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) by the global medical community—is increasingly classified by experts as the "diabetes of the ovaries" due to its root foundation in severe insulin resistance.
The Landmark Shift from PCOS to PMOS Explained
For several decades, millions of women across India have lived with a clinical label that many specialists argue fundamentally misrepresented their condition. In May 2026, a consensus within international medical bodies officially modified the terminology from Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
According to clinical publications from the Indian Council of Medical Research (ICMR), the old name mistakenly implied that the presence of benign, fluid-filled follicles on the ovaries was the primary issue. In reality, the syndrome is a multi-system endocrine disorder. The updated terminology places necessary focus on the interconnected hormonal and metabolic disruptions that impact a patient's cardiovascular system, skin health, psychological well-being, and long-term fertility.
Why Experts Call the Condition 'Diabetes of the Ovaries'
The comparison to type 2 diabetes mellitus stems from the underlying role that insulin resistance plays in driving the disorder. According to data published by the World Health Organization (WHO), insulin resistance affects roughly 70% to 80% of overweight patients diagnosed with PMOS, as well as 20% to 30% of lean individuals with the condition.
When human cells fail to respond effectively to insulin, the pancreas compensates by overproducing the hormone. This excess insulin interacts directly with the ovaries, stimulating them to produce high levels of androgens, such as testosterone. These elevated male hormones disrupt the normal reproductive cycle, preventing immature follicles from developing fully and releasing healthy eggs. This breakdown in communication effectively creates a localized metabolic block within the female reproductive tract, making the condition a leading cause of ovulatory infertility.
India's Rapidly Growing Fertility and Infertility Dilemma
The rapid spread of PMOS across urban and rural landscapes is a major driver of the country's shifting reproductive trends. Recent data shows that India faces an unusually high prevalence of the disorder, with roughly 20% to 25% of reproductive-aged Indian women affected, compared to a global average of 10% to 13%.
Medical experts note that South Asian populations have a distinct genetic predisposition to abdominal adiposity and insulin resistance, even at lower Body Mass Index (BMI) levels. This biological vulnerability, compounded by highly processed modern diets, chronic stress, and increasingly sedentary lifestyles, has turned PMOS into a significant healthcare challenge. The resulting rise in irregular or absent menstrual cycles has made the disorder the primary driver of anovulatory subfertility across the country.
Impact on Consumers, Patients, and Healthcare Providers
The growing focus on PMOS is reshaping operational strategies and personal choices across multiple areas of society:
Patients and Consumers: Women experiencing irregular periods, unexpected weight gain, severe cystic acne, or difficulty conceiving are being urged to move away from quick-fix cosmetic or menstrual treatments. Proper management requires seeking comprehensive metabolic screening, including fasting insulin and lipid profile evaluations.
Medical Practitioners: Gynecologists and endocrinologists are shifting toward a cross-disciplinary treatment framework. Rather than simply prescribing oral contraceptives to force a regular withdrawal bleed, contemporary protocols focus on managing underlying insulin levels through metabolic care.
The Healthcare and IVF Sector: For couples seeking assistance from the fertility sector, specialists note that while PMOS presents a significant hurdle to natural conception, it remains highly treatable. Advanced techniques like low-dose ovarian stimulation and frozen embryo transfers are increasingly used to maximize pregnancy success rates while protecting patient safety.
Official Sources Section
The biochemical findings, diagnostic standards, and demographic metrics presented in this article are derived from official bulletins published by the World Health Organization (WHO), multicentric studies conducted by the Indian Council of Medical Research (ICMR), and clinical updates issued by the Federation of Obstetricians and Gynaecologists of India.
Quote Section
"India is facing a twin challenge of falling fertility rates and rising infertility, while millions of women continue to battle a hormonal condition that experts say is often misunderstood as merely a reproductive disorder. The recent renaming of PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) is an attempt to change that narrative."
— Dr. Rishma Pai, Leading Indian Gynecologist
Why It Matters
Reclassifying the condition as a systemic metabolic disorder has significant practical implications for public health management. When patients and physicians view PMOS primarily as a gynecological issue, treatment often stops once a woman successfully conceives or finishes her childbearing years. However, treating the condition like "diabetes of the ovaries" underscores that the metabolic risks remain throughout a patient's life, requiring lifelong monitoring to prevent the subsequent development of type 2 diabetes, fatty liver disease, and long-term cardiovascular complications.
Key Facts at a Glance
The Core Rename: The medical community has officially changed the name of PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect its multi-system nature.
High Local Prevalence: PMOS affects an estimated 20% to 25% of reproductive-aged women in India, significantly exceeding the global average.
Primary Driver: Severe insulin resistance serves as the core mechanism, causing the ovaries to overproduce male hormones and blocking normal ovulation.
Fertility Impact: The disorder is recognized as the leading cause of ovulatory subfertility among young women nationwide.
FAQ Section
Q1: Why was the name changed from PCOS to PMOS? The old name focused heavily on ovarian cysts, which are actually just underdeveloped follicles. The new name, Polyendocrine Metabolic Ovarian Syndrome, properly highlights that the condition is a complex hormonal and metabolic disorder affecting multiple systems in the body.
Q2: Does having PMOS mean a woman will definitely develop diabetes? Not necessarily, but it indicates a much higher risk. Because insulin resistance is a central driver of the condition, women with PMOS face an elevated likelihood of developing type 2 diabetes later in life if the underlying metabolic issues are left unmanaged.
Q3: Can women with PMOS still achieve a successful pregnancy? Yes. While PMOS is a leading cause of fertility challenges due to irregular ovulation, it is highly manageable. Most patients can achieve successful pregnancies through targeted lifestyle changes, first-line ovulation medications, or assisted reproductive technologies like IVF.
